- In October 2022, Orthofix announced the first patient implants using its Legacy Demineralized Bone Matrix (DBM) for spine, pelvic, and extremity procedures. This DBM product is designed to enhance bone regeneration and serves as an advanced bone grafting solution. The product features proven osteoinductive properties and is processed to retain essential growth factors, improving bone healing outcomes. The launch of Legacy DBM reinforces the growing demand for advanced bone graft substitutes, contributing to market expansion
- In September 2022, Ossifix Orthopedics introduced its Demineralized Bone Matrix (DBM) Crunch, a bone grafting product designed to promote new bone growth. This DBM Crunch contains cancellous bone fragments within the matrix, providing an osteoconductive scaffolding that supports bone regeneration. Ossifix Orthopedics' introduction of DBM Crunch adds to the variety of bone grafting options available, catering to diverse surgical needs and patient requirements
- In March 2022, Bone Biologics Corporation announced a supply agreement with MTF Biologics for demineralized bone matrix (DBM). This agreement marks a significant milestone, enabling the company to advance rhNELL-1 for the USD 3 billion spine fusion market. The objective is to develop a superior product with enhanced features and benefits compared to existing commercial offerings
- In September 2021, Essent Biologics announced the launch of its Spectral Demineralized Bone Matrix (DBM), the first human-derived DBM specifically designed for 3D bioprinting and tissue engineering research. This osteoconductive DBM powder, derived from adult human cortical bone, also possesses osteogenic potential. The launch aims to advance research in next-generation bone therapeutics, validate its practical applications, and explore opportunities to improve bone repair outcomes
- In July 2021, RTI Surgical entered into a long-term strategic agreement with global medical device OEM Exactech for the development and supply of biologic bone substitutes. As part of this agreement, RTI Surgical acquired Optecure, a 510(k)-cleared demineralized bone matrix (DBM) from Exactech, designed for use as a bone graft extender in spinal, pelvic, and extremity procedures
